Biodesix (Biodesix) Current Accrued Expense : $4.43 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biodesix Current Accrued Expense?

Biodesix's Current Accrued Expense for the quarter that ended in Mar. 2024 was $4.43 Mil.

Biodesix's quarterly Current Accrued Expense increased from Sep. 2023 ($3.68 Mil) to Dec. 2023 ($3.86 Mil) and increased from Dec. 2023 ($3.86 Mil) to Mar. 2024 ($4.43 Mil).

Biodesix's annual Current Accrued Expense declined from Dec. 2021 ($3.64 Mil) to Dec. 2022 ($3.55 Mil) but then increased from Dec. 2022 ($3.55 Mil) to Dec. 2023 ($3.86 Mil).

Biodesix Current Accrued Expense Historical Data

The historical data trend for Biodesix's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Current Accrued Expense Chart

Biodesix Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

2.97

3.81

3.64

3.55

3.86

Biodesix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															2.65	3.07	3.68	3.86	4.43

Biodesix Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Biodesix Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biodesix's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodesix (Biodesix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301

Website

https://www.biodesix.com

Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Executives

Scott Hutton	director, officer: President & CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane	officer: Chief Commercial Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano	officer: Chief Development Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie	officer: CFO, Sec'y & Treasurer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez	officer: Chief Accounting Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr	director, 10 percent owner	C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek	officer: Chief Accounting Officer	6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience	director, 10 percent owner, other: Chairman	28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii	director, officer: SVP, Rsrch & Trans'l Science	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139